Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Sep;72(3):1034–1041. doi: 10.1172/JCI111027

"Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.

M Matsuda, M Baba, K Morimoto, C Nakamikawa
PMCID: PMC1129270  PMID: 6886002

Abstract

A hereditary dysfibrinogenemia associated with defective aggregation of fibrin monomers was found in a 39-yr-old female and in the members of her immediate family, who had all been asymptomatic. The abnormality was probably due to an impaired polymerization site exposed in the DD domain of two adjacent fibrin molecules, because plasmic fragment DD derived from the propositus' cross-linked fibrin bound far less tightly to insolubilized normal fragment E than that from the normal one. Its complementary polymerization site in the E domain of fibrin, which was exposed by thrombin cleavage, and the polymerization site in the D domain of fibrinogen, which was available without activation by thrombin, were both found to be normal. More anodal migration of the abnormal fragment DD than the normal one, as shown by immunoelectrophoresis, seemed to support our concept that the mutation most likely resides in the D domain of the abnormal fibrinogen molecule at or near a region closely related to the polymerization site that is exposed when two fibrin molecules are linearly aligned. The work of others on the polymerization of normal fibrin with different techniques yielded results consistent with our conclusions. We tentatively designate this type of abnormal fibrinogen "fibrinogen Tokyo II," but its possible identity with other abnormalities of fibrinogen reported heretofore is not excluded.

Full text

PDF
1034

Images in this article

1036FIGURE 1
on p.1036
1038FIGURE 5
on p.1038
1038FIGURE 7
on p.1038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki N., Moroi M., Sakata Y., Yoshida N., Matsuda M. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest. 1978 May;61(5):1186–1195. doi: 10.1172/JCI109034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blombäck M., Blombäck B., Mammen E. F., Prasad A. S. Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968 Apr 13;218(5137):134–137. doi: 10.1038/218134a0. [DOI] [PubMed] [Google Scholar]
  3. Boyer M. H., Shainoff J. R., Ratnoff O. D. Acceleration of fibrin polymerization by calcium ions. Blood. 1972 Mar;39(3):382–387. [PubMed] [Google Scholar]
  4. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  5. Cuatrecasas P., Wilchek M., Anfinsen C. B. Selective enzyme purification by affinity chromatography. Proc Natl Acad Sci U S A. 1968 Oct;61(2):636–643. doi: 10.1073/pnas.61.2.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Curtis C. G., Lorand L. Fibrin-stabilizing factor (factor XIII). Methods Enzymol. 1976;45:177–191. doi: 10.1016/s0076-6879(76)45018-8. [DOI] [PubMed] [Google Scholar]
  7. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  8. Engvall E., Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer. 1977 Jul 15;20(1):1–5. doi: 10.1002/ijc.2910200102. [DOI] [PubMed] [Google Scholar]
  9. Fowler W. E., Hantgan R. R., Hermans J., Erickson H. P. Structure of the fibrin protofibril. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4872–4876. doi: 10.1073/pnas.78.8.4872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gralnick H. R., Givelber H. M., Shainoff J. R., Finlayson J. S. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest. 1971 Sep;50(9):1819–1830. doi: 10.1172/JCI106673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kudryk B. J., Collen D., Woods K. R., Blombäck B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem. 1974 May 25;249(10):3322–3325. [PubMed] [Google Scholar]
  12. Kudryk B., Blombäck B., Blombäck M. Fibrinogen Detroit - an abnormal fibrinogen with non-functinal NH2-terminal polymerization domain. Thromb Res. 1976 Jul;9(1):25–36. doi: 10.1016/0049-3848(76)90146-8. [DOI] [PubMed] [Google Scholar]
  13. LORAND L., KONISHI K. ACTIVATION OF THE FIBRIN STABILIZING FACTOR OF PLASMA BY THROMBIN. Arch Biochem Biophys. 1964 Apr;105:58–67. doi: 10.1016/0003-9861(64)90235-8. [DOI] [PubMed] [Google Scholar]
  14. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  15. Lorand L., Urayama T., De Kiewiet J. W., Nossel H. L. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969 Jun;48(6):1054–1064. doi: 10.1172/JCI106061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lundblad R. L. A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride. Biochemistry. 1971 Jun 22;10(13):2501–2506. doi: 10.1021/bi00789a012. [DOI] [PubMed] [Google Scholar]
  17. Marder V. J., Budzyński A. Z., James H. L. High molecular weight derivatives of human fibrinogen produced by plasmin. 3. Their NH2-terminal amino acids and comparison with the "NH2-terminal disulfide knot". J Biol Chem. 1972 Aug 10;247(15):4775–4781. [PubMed] [Google Scholar]
  18. Mosher D. F. Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J Biol Chem. 1975 Aug 25;250(16):6614–6621. [PubMed] [Google Scholar]
  19. Ménaché D. Abnormal fibrinogens. A review. Thromb Diath Haemorrh. 1973 Jun 28;29(3):525–535. [PubMed] [Google Scholar]
  20. Olexa S. A., Budzynski A. Z., Doolittle R. F., Cottrell B. A., Greene T. C. Structure of fragment E species from human cross-linked fibrin. Biochemistry. 1981 Oct 13;20(21):6139–6145. doi: 10.1021/bi00524a035. [DOI] [PubMed] [Google Scholar]
  21. Olexa S. A., Budzynski A. Z. Effects of fibrinopeptide cleavage on the plasmic degradation pathways of human cross-linked fibrin. Biochemistry. 1980 Feb 19;19(4):647–651. doi: 10.1021/bi00545a007. [DOI] [PubMed] [Google Scholar]
  22. Olexa S. A., Budzynski A. Z. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1374–1378. doi: 10.1073/pnas.77.3.1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Olexa S. A., Budzynski A. Z. Primary soluble plasmic degradation product of human cross-linked fibrin. Isolation and stoichiometry of the (DD)E complex. Biochemistry. 1979 Mar 20;18(6):991–995. doi: 10.1021/bi00573a009. [DOI] [PubMed] [Google Scholar]
  24. RATNOFF O. D., MENZIE C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med. 1951 Feb;37(2):316–320. [PubMed] [Google Scholar]
  25. Sakata Y., Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980 Feb;65(2):290–297. doi: 10.1172/JCI109671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tamaki T., Aoki N. Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta. 1981 Oct 13;661(2):280–286. doi: 10.1016/0005-2744(81)90016-4. [DOI] [PubMed] [Google Scholar]
  27. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES